Option Care Health, Inc. 10-Q

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Unless the context requires otherwise, references in this report to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries. Management’s discussion and analysis of financial condition and results of operations (“MD&A”) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial condition. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and the related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q (this “Form 10-Q”). Certain statements in this Item 2 of Part I of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2023 (our “Form 10-K”), may cause our actual results, financial position, and cash and cash equivalents generated from operations to differ materially from these forward-looking statements. Business Overview Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 182 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, and dietitians work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions. Update on the Impact of the Change Healthcare Cybersecurity Incident As previously disclosed, Change Healthcare, a subsidiary of UnitedHealth Group, experienced an incident on February 21, 2024, in which a cybersecurity threat actor gained access to some of its information technology systems (“Change Healthcare Cybersecurity Incident”). Since the time of the system disruption, Option Care Health has worked continuously to find alternative processes to help maintain patient care and overall operations. As of June 30, 2024, the Company has not identified any compromise or unauthorized access of its systems or networks due to this third party incident. As of the end of the second quarter of 2024, the Company reconnected to key applications maintained by Change Healthcare and resumed claims submission to payers, however, certain functionality remains disrupted. The Company continues to work through accumulated unprocessed billing and to establish full recovery from the Change Healthcare Cybersecurity Incident. During the second quarter of 2024, the Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on the financial results as reported. The Company continues to maintain strong liquidity and, having resumed submission of a majority of claims to payers, has determined that the Change Healthcare Cybersecurity Incident is not reasonably likely to materially impact the Company, including its business operations, financial condition or results of operations. 20 Table of Contents Composition of Results of Operations The following results of operations include the accounts of Option Care Health and our subsidiaries for the three and six months ended June 30, 2024 and 2023. Gross Profit Gross profit represents our net revenue less cost of revenue. Net Revenue. Infusion and related health care services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered. Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded. Cost of Revenue. Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient. The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold. Operating Costs and Expenses Selling, General and Administrative Expenses . Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees. Depreciation and Amortization Expense. Depreciation within this caption relates to fixed assets and amortization relates to intangibles. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue. Other Income (Expense) Interest Expense, Net . Interest expense consists principally of interest and fee payments on the Company’s outstanding borrowings under the First Lien Term Loan, Revolver Facility, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the “Liquidity and Capital Resources” section below for further discussion of these outstanding borrowings. Equity in Earnings of Joint Ventures . Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems. Other, Net . Other income (expense) primarily includes activity related to non-operating income and expenses. Income Tax Expense . The Company is subject to taxation in the United States and various states. The Company’s income tax expense is reflective of the current federal and state tax rates. Change in Unrealized (Loss) Gain on Cash Flow Hedge, Net of Income Tax Benefit (Expense) . Change in unrealized (loss) gain on cash flow hedge, net of income tax benefit (expense), consists of the (loss) gain associated with the changes in the fair value of derivatives designated as hedging instruments related to the interest rate cap hedge, net of income taxes. 21 Table of Contents Results of Operations The following table presents Option Care Health’s consolidated results of operations for the three and six months ended June 30, 2024 and 2023 (in thousands, except for percentages): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue NET REVENUE $ 1,227,186 100.0 % $ 1,069,072 100.0 % $ 2,373,238 100.0 % $ 2,084,920 100.0 % COST OF REVENUE 977,821 79.7 % 818,243 76.5 % 1,885,373 79.4 % 1,605,086 77.0 % GROSS PROFIT 249,365 20.3 % 250,829 23.5 % 487,865 20.6 % 479,834 23.0 % OPERATING COSTS AND EXPENSES: Selling, general and administrative expenses 153,783 12.5 % 153,564 14.4 % 308,525 13.0 % 301,430 14.5 % Depreciation and amortization expense 14,907 1.2 % 14,898 1.4 % 29,635 1.2 % 29,412 1.4 % Total operating expenses 168,690 13.7 % 168,462 15.8 % 338,160 14.2 % 330,842 15.9 % OPERATING INCOME 80,675 6.6 % 82,367 7.7 % 149,705 6.3 % 148,992 7.1 % OTHER INCOME (EXPENSE): Interest expense, net (12,603) (1.0) % (13,196) (1.2) % (25,805) (1.1) % (27,030) (1.3) % Equity in earnings of joint ventures 1,405 0.1 % 1,397 0.1 % 2,530 0.1 % 2,834 0.1 % Other, net 2,564 0.2 % 84,935 7.9 % 2,566 0.1 % 84,936 4.1 % Total other (expense) income (8,634) (0.7) % 73,136 6.8 % (20,709) (0.9) % 60,740 2.9 % INCOME BEFORE INCOME TAXES 72,041 5.9 % 155,503 14.5 % 128,996 5.4 % 209,732 10.1 % INCOME TAX EXPENSE 18,998 1.5 % 41,100 3.8 % 31,162 1.3 % 56,121 2.7 % NET INCOME $ 53,043 4.3 % $ 114,403 10.7 % $ 97,834 4.1 % $ 153,611 7.4 % OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX: Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $242, $(1,103), $(213) and $49, respectively (899) (0.1) % 3,291 0.3 % 652 — % (152) — % OTHER COMPREHENSIVE (LOSS) INCOME (899) (0.1) % 3,291 0.3 % 652 — % (152) — % NET COMPREHENSIVE INCOME $ 52,144 4.2 % $ 117,694 11.0 % $ 98,486 4.1 % $ 153,459 7.4 % 22 Table of Contents Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the three months ended June 30, 2024 and 2023. Gross Profit Three Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Net revenue $ 1,227,186 $ 1,069,072 $ 158,114 14.8 % Cost of revenue 977,821 818,243 159,578 19.5 % Gross profit $ 249,365 $ 250,829 $ (1,464) (0.6) % Gross profit margin 20.3 % 23.5 % The increase in net revenue was primarily driven by organic growth in the Company’s broad portfolio of acute and chronic therapies, consisting of acute revenue that had single-digit growth relative to the prior year while chronic revenue grew in the mid-teens. The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024. Operating Expenses Three Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Selling, general and administrative expenses $ 153,783 $ 153,564 $ 219 0.1 % Depreciation and amortization expense 14,907 14,898 9 0.1 % Total operating expenses $ 168,690 $ 168,462 $ 228 0.1 % Selling, general and administrative expenses during the three months ended June 30, 2024 was relatively consistent with prior year; however, these expenses have declined as a percentage of revenue to 12.5% for the three months ended June 30, 2024 compared to 14.4% for the three months ended June 30, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending. 23 Table of Contents Other Income (Expense) Three Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Interest expense, net $ (12,603) $ (13,196) $ 593 (4.5) % Equity in earnings of joint ventures 1,405 1,397 8 0.6 % Other, net 2,564 84,935 (82,371) (97.0) % Total other (expense) income $ (8,634) $ 73,136 $ (81,770) (111.8) % The decrease in interest expense, net during the three months ended June 30, 2024 was primarily attributable to additional interest income generated from our cash and cash equivalents, partially offset by an increase in the Company’s First Lien Term Loan variable interest rate, compared to the three months ended June 30, 2023. See Note 9, Indebtedness , of the unaudited condensed consolidated financial statements for further information. The decrease in Other, net during the three months ended June 30, 2024 was due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the three months ended June 30, 2023. There was no comparable activity during the three months ended June 30, 2024. Income Tax Expense Three Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Income tax expense $ 18,998 $ 41,100 $ (22,102) (53.8) % The Company recorded income tax expense of $19.0 million and $41.1 million for the three months ended June 30, 2024 and 2023, respectively, which represents an effective tax rate of 26.4% and 26.4%, respectively. The income tax expense for the three months ended June 30, 2023 includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The variance in the Company’s effective tax rate of 26.4% for the three months ended June 30, 2024, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.4% for the three months ended June 30, 2023, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses. 24 Table of Contents Net Income and Other Comprehensive Income (Loss) Three Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Net income $ 53,043 $ 114,403 $ (61,360) (53.6) % Other comprehensive (loss) income, net of tax: Changes in unrealized (loss) gain on cash flow hedges, net of income taxes (899) 3,291 (4,190) (127.3) % Other comprehensive (loss) income (899) 3,291 (4,190) (127.3) % Net comprehensive income $ 52,144 $ 117,694 $ (65,550) (55.7) % The change in net income was attributable to organic growth from additional revenue related to the factors described in the above sections in addition to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the three months ended June 30, 2023. There was no comparable activity during the three months ended June 30, 2024. For the three months ended June 30, 2024 and 2023, the change in unrealized gain on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021. Net comprehensive income decreased to $52.1 million for the three months ended June 30, 2024, compared to net comprehensive income of $117.7 million for the three months ended June 30, 2023, primarily as a result of the changes in net income discussed above. 25 Table of Contents Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the six months ended June 30, 2024 and 2023. Gross Profit Six Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Net revenue $ 2,373,238 $ 2,084,920 $ 288,318 13.8 % Cost of revenue 1,885,373 1,605,086 280,287 17.5 % Gross profit $ 487,865 $ 479,834 $ 8,031 1.7 % Gross profit margin 20.6 % 23.0 % The increase in net revenue was primarily driven by organic growth in the Company’s broad portfolio of acute and chronic therapies, consisting of acute revenue that had single-digit growth relative to the prior year while chronic revenue grew in the mid-teens. The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024. Operating Expenses Six Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Selling, general and administrative expenses $ 308,525 $ 301,430 $ 7,095 2.4 % Depreciation and amortization expense 29,635 29,412 223 0.8 % Total operating expenses $ 338,160 $ 330,842 $ 7,318 2.2 % The increase in selling, general and administrative expenses during the six months ended June 30, 2024 was primarily due to an increase in salaries, benefits, and equity compensation; however, these expenses have declined as a percentage of revenue to 13.0% for the six months ended June 30, 2024 compared to 14.5% for the six months ended June 30, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending. 26 Table of Contents Other Income (Expense) Six Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Interest expense, net $ (25,805) $ (27,030) $ 1,225 (4.5) % Equity in earnings of joint ventures 2,530 2,834 (304) (10.7) % Other, net 2,566 84,936 (82,370) (97.0) % Total other (expense) income $ (20,709) $ 60,740 $ (81,449) (134.1) % The decrease in interest expense, net during the six months ended June 30, 2024 was primarily attributable to additional interest income generated from our cash and cash equivalents, partially offset by an increase in the Company’s First Lien Term Loan variable interest rate, compared to the six months ended June 30, 2023. See Note 9, Indebtedness , of the unaudited condensed consolidated financial statements for further information. The decrease in Other, net during the six months ended June 30, 2024 was due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the six months ended June 30, 2023. There was no comparable activity during the six months ended June 30, 2024. Income Tax Expense Six Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Income tax expense $ 31,162 $ 56,121 $ (24,959) (44.5) % The Company recorded income tax expense of $31.2 million and $56.1 million for the six months ended June 30, 2024 and 2023, respectively, which represents an effective tax rate of 24.2% and 26.8%, respectively. The income tax expense for the six months ended June 30, 2023 includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The variance in the Company’s effective tax rate of 24.2% for the six months ended June 30, 2024, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.8% for the six months ended June 30, 2023, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, as well as various non-deductible expenses. 27 Table of Contents Net Income and Other Comprehensive Income (Loss) Six Months Ended June 30, 2024 2023 Variance (in thousands, except for percentages) Net income $ 97,834 $ 153,611 $ (55,777) (36.3) % Other comprehensive income (loss), net of tax: Changes in unrealized gain (loss) on cash flow hedges, net of income taxes 652 (152) 804 528.9 % Other comprehensive income (loss) 652 (152) 804 528.9 % Net comprehensive income $ 98,486 $ 153,459 $ (54,973) (35.8) % The change in net income was attributable to organic growth from additional revenue related to the factors described in the above sections in addition to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the six months ended June 30, 2023. There was no comparable activity during the six months ended June 30, 2024. For the six months ended June 30, 2024 and 2023, the change in unrealized gain on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021. Net comprehensive income decreased to $98.5 million for the six months ended June 30, 2024, compared to net comprehensive income of $153.5 million for the six months ended June 30, 2023, primarily as a result of the changes in net income discussed above. 28 Table of Contents Liquidity and Capital Resources For the six months ended June 30, 2024 and the twelve months ended December 31, 2023, the Company’s primary sources of liquidity were cash and cash equivalents of $376.9 million and $343.8 million, respectively. As of June 30, 2024, the Company had $395.9 million of borrowings available under its credit facilities (net of $4.1 million undrawn letters of credit issued and outstanding). As of December 31, 2023, the Company had $394.7 million of borrowings available under its credit facilities (net of $5.3 million undrawn letters of credit issued and outstanding). During the six months ended June 30, 2024, the Company’s cash flows from operations were impacted by the Change Healthcare Cybersecurity Incident. See the caption “Update on the Impact of the Change Healthcare Cybersecurity Incident” included in this Form 10-Q for further discussion. During the twelve months ended December 31, 2023, the Company’s cash flows from operations enabled investments in pharmacy, infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases. The Company’s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, the pursuit of acquisitions, and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt and cash taxes. Ongoing investing cash flows are primarily associated with capital projects related to business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt, along with potential future share repurchases. Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash and cash equivalents with the exception of the BioScrip merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms. Short-Term and Long-Term Liquidity Requirements The Company’s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements over the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans. 29 Table of Contents Credit Facilities The Company’s Revolver Facility provides for borrowings up to $400.0 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility will bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent compliance certificate received by the Administrative Agent pursuant to the terms of the credit agreement. As of June 30, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. In May 2024, the Company entered into the Third Amendment on the First Lien Term Loan. The Third Amendment, among other things, (i) provides for an additional $50.0 million of incremental First Lien Term Loan indebtedness and (ii) reduces the interest rate on the First Lien Term Loan from Term SOFR (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan. The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment). The Senior Notes bear interest at a rate of 4.375% per annum and are payable semi-annually in arrears on October 31 and April 30 of each year, which began on April 30, 2022. The Senior Notes mature on October 31, 2029. Interest payments over the course of long-term debt obligations total an estimated $325.0 million based on final maturity dates of the Company’s credit facilities. Interest payments are calculated based on current rates as of June 30, 2024. Actual payments are based on changes in SOFR and exclude the interest rate cap derivative instrument. 30 Table of Contents Cash Flows Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 The following table presents selected data from Option Care Health’s unaudited condensed consolidated statements of cash flows: Six Months Ended June 30, 2024 2023 Variance (in thousands) Net cash provided by operating activities $ 126,871 $ 259,288 $ (132,417) Net cash used in investing activities (15,597) (26,409) 10,812 Net cash used in financing activities (78,251) (85,899) 7,648 Net increase in cash and cash equivalents 33,023 146,980 (113,957) Cash and cash equivalents - beginning of period 343,849 294,186 49,663 Cash and cash equivalents - end of period $ 376,872 $ 441,166 $ (64,294) Cash Flows from Operating Activities The decrease in cash provided in operating activities during the six months ended June 30, 2024, as compared to the six months ended June 30, 2023, was primarily due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, and changes in accounts receivable, accrued compensation and employee benefits, changes in prepaid expenses, and other current liabilities, offset by purchasing of additional inventory and changes in accounts payable. Cash Flows from Investing Activities The change in cash used in investing activities during the six months ended June 30, 2023 was primarily due to prior year acquisition activity with no comparable activity within the six months ended June 30, 2024. Cash Flows from Financing Activities The decrease in cash used in financing activities was primarily related to the Company’s debt refinancing in May 2024, in which $50.0 million in proceeds from issuance of debt was received offset by $118.1 million in repurchase of common stock during the six months ended June 30, 2024, with no comparable activity during the six months ended June 30, 2023. The cash used in financing activities during the six months ended June 30, 2023 was primarily related to the Company’s $75.0 million repurchase of common stock. Critical Accounting Policies and Estimates The Company prepares its unaudited condensed consolidated financial statements in accordance with GAAP, which requires the Company to make estimates and assumptions. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making assumptions about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company’s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates. There have been no material changes to the Company’s critical accounting policies and estimates as presented in our Form 10-K, which are hereby incorporated by reference. 31 Table of Contents Item 3. Quantitative and Qualitative Disclosures about Market Risk There have been no material changes to our exposure to market risk from those included in our Form 10-K, which is hereby incorporated by reference.